SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mo_lucre who wrote (19)12/16/2006 6:07:01 PM
From: Keith Feral of 418
 
I hate to make informed guesses about something that Adventrx could not even guess at this point. I totally think the BMY or IMCL is a potential partner, but I don't see any reason for a 3 way deal. IMCL would be smart to use it's own stock as currency to leverage a partnership with ANX. That deal would not include BMY in any way shape or form.

I don't even feel like taking a guess who will be the marketing partner. I just like to think that the company is doing everything to wait for the best deal. The phase 2 b only has 2 more months until the clinicals are done in Europe. Then, it will take a few more months to get the data ready for ASCO in June. In the meantime, the company needs to continue ramping enrollment for the phase 3 with Avastin. Once they get to 400 patients, the drug can be fast tracked if the data is strong. It only took 12 months for the phase 2 b enrollement in Europe, so the first peak at the phase 3 data could be ready by this summer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News